Revital Aricha, PhD

VP RESEARCH & DEVELOPMENT
Dr. Revital Aricha joined Cell-Gene company in March 2015 and serves as Vice President of Research and Development. Prior to joining Cell-Gene company, she served as Senior Intern at the Department of Immunology of the Weizmann Institute of Science since 2006, where she specialized in autoimmunity related to neuromuscular pathology and regulatory processes.
Dr. Aricha completed her postdoctoral fellowship at the Weizmann Institute of Science. She received her PhD in Neurobiology summa cum laude from the Bar-Ilan University, where she studied Parkinson’s disease.
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.